Nutraceutical Division

From mechanism of action to the dossier that supports it

BiCT is the R&D laboratory of companies that develop branded ingredients and actives, and of those bringing own-brand supplements to market. We work on the mechanism with multi-model in vitro studies, on the stability and bioaccessibility of the active, and on benchmarking against category references under the same conditions. Not isolated tests: the experimental design that supports what the product claims.

Let's talk about your project
WHO WE WORK FOR

Who we work for

Two clients, one scientific platform.

Ingredient & branded active companies

Producers of bioactive ingredients obtained through biotechnological processes such as fermentation, and of extracts. You need scientific evidence and dossiers to position your active on global B2B markets.

What you are looking for: mechanism-of-action validation · comparative efficacy validation vs top sellers · stability, bioaccessibility and bioavailability testing · analytical method development · publication or patent · guiding or strengthening clinical trials · dossiers and communication for your sales force and for the customers who develop the finished product.

Finished-product supplement companies

Nutraceutical brands, contract manufacturers and distributors launching new lines or strengthening existing ones. You need distinctive products, evidence and a scientific narrative for your sales force.

What you are looking for: differentiating concepts · multi-model in vitro studies · stability, bioaccessibility and bioavailability testing · competitor benchmarking · analytical method development · guiding or strengthening clinical trials · building a technical dossier · publication or patent.

A nutraceutical claim is defended with data

Regulation EC 1924/2006 governs what a supplement may state on its label, and the perimeter of authorised claims is narrow. What falls outside it — mechanism, bioaccessibility, benchmarking against references — never reaches the pack, but it decides the technical conversation: with the formulator downstream, with the buyer, with the doctor and the pharmacist.

Without data of your own, that conversation is held in your competitor's words.

What we solve

Four points at which a nutraceutical project stalls, and the data that gets it moving again.

The data does not survive review
Multi-model studies with controls and declared experimental conditions, in the form a referee or a downstream customer can verify
The mechanism is claimed, not measured
Markers chosen for the mechanism you need to document, not from a catalogue: we measure the pathway the product says it acts on
The active works isolated, not in the formulation
Stability, bioaccessibility and biological activity measured on the final formulation, not only on the isolated ingredient
The comparison with the top seller is an opinion
A comparative study under the same conditions, with the category reference handled exactly as your active
THREE PATHS

How we work: three paths to your objective

We do not sell single tests: the plan is built on the claim you need to support and on the reader who will have to accept it.

1

Ingredient validation and valorisation

For ingredient companies.

We translate bioactivity into evidence your downstream customers can adopt: a technical and commercial dossier, a scientific publication, a patent.

2

Supplement valorisation and formulation development

For ingredient and finished-product companies.

We move formulation from a marketing choice to a scientific one — including validation of biological efficacy on the final formulation, not only on the isolated ingredient.

3

New ingredient development

An additional capability.

When innovation calls for a new ingredient, we develop the underlying process — from fermentation or extraction through to prototype — for those who want to own the scientific and manufacturing base.

BENEFITS

Where the data is used

A technical dossier has more than one reader: these are the ones we write it for.

Development directionwhich candidates go forward and which stop, decided on data
Scientific positioningoriginal models and design, not the ones in everybody else's dossier
Material for the sales forcethe same evidence rewritten for those who talk to doctors and pharmacists
Presenting new conceptsto internal stakeholders, partners and downstream customers
Publication and patentdata generated from the outset in the form that makes it usable
Preparing the clinical studyendpoints and population chosen on preclinical evidence

Where do we start?

I am an ingredient company

I am a finished-product company

I am not sure where to start

Tell us about the active and what it has to demonstrate

From the district it acts on and the claim you need to support, we derive the models, the endpoints and the shape of the dossier. That is exactly what the first conversation is for.

Contact us